Trial Profile

Dose-ascending, Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lonapegsomatropin (Primary) ; Growth hormones
Indications Somatotropin deficiency
Focus Adverse reactions; First in man; Pharmacokinetics
Acronyms TransCon PEG hGH
Sponsors Ascendis Pharma

Most Recent Events

19 Mar 2018 According to Ascendis Pharma media release, interim data from this trial will be presented at ENDO 2018
04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
04 Apr 2016 Results assessing optimal release profile of unmodified hGH from the prodrug and to predict the relationship between TransCon Growth Hormone dose and serum concentrations of released unmodified hGH presented at The 98th Annual Meeting of the Endocrine Society.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com